Last year US Patent office granted another patent (US Patent No 7,544,369) covering Transave Arikace for the sustained release of antibiotic and once-daily treatment of Pseudomonas lung infections.
Tim Whitten, CEO of Transave, said: “The issuance of this composition of matter patent significantly strengthens the intellectual property estate around Arikace and represents a valuable asset for Transave.
“We are continuing to secure and expand our proprietary position for Arikace which has the potential to become an important treatment for cystic fibrosis (CF) patients with Pseudomonas lung infections, non-CF bronchiectasis patients with Pseudomonas lung infections, and patients with nontuberculous mycobacteria (NTM) lung infections. We look forward to moving to Phase 3 as soon as possible.”